Full-Time

CMC Regulatory Affairs Director

Jade Biosciences

Jade Biosciences

51-200 employees

Develops, licenses, and commercializes biologic therapies

Compensation Overview

$210k - $235k/yr

Remote in USA

Remote

Fully remote; periodic travel to team and company events.

Bachelor's

Category
Legal & Compliance (1)

Get referred to Jade Biosciences

See people who can refer or advise you

Requirements
  • Bachelor’s degree in a scientific discipline, such as Life Sciences, Biotechnology, Pharmaceutical Sciences, or a related field.
  • Minimum of 10 years of experience in Regulatory Affairs, CMC, or related pharmaceutical or biotechnology functions, with significant biologics experience.
  • Proven experience developing and executing global CMC regulatory strategies for biologics across clinical and commercial stages.
  • Strong knowledge of global CMC regulatory requirements and experience with INDs, IMPDs, CTAs, BLAs, MAAs, and post-approval submissions.
  • Solid understanding of biologics and combination product development and manufacturing, including analytical methods, process validation, comparability, specifications, and stability.
  • Experience supporting health authority interactions, including regulatory meetings and responses to agency questions.
  • Ability to assess regulatory impacts of product, process, manufacturing, and lifecycle changes and develop appropriate regulatory strategies.
  • Strong leadership, project management, communication, and cross-functional collaboration skills.
Responsibilities
  • Develop and implement global CMC regulatory strategies for biologic and combination products.
  • Prepare and manage CMC submissions, briefing documents, and health authority meeting packages, including INDs, CTAs, BLAs, MAAs, and post-approval filings, etc.
  • Serve as the CMC Regulatory lead on cross-functional project teams.
  • Support health authority interactions and responses to regulatory questions.
  • Provide regulatory guidance on manufacturing, analytical, quality, and lifecycle topics.
  • Assess regulatory impact of manufacturing and lifecycle changes and develop risk mitigation strategies.
  • Collaborate with internal teams and external partners to support development and commercialization.
  • Stay abreast of regulatory trends, guidance documents, and changes to global regulatory requirements affecting CMC.
  • Support product release, investigations, inspections, and relevant SOP reviews.
Desired Qualifications
  • Experience with biologics and combination products, including prefilled syringes and autoinjectors, is preferred.

Jade Biosciences develops and commercializes biologic therapies. It builds a pipeline of potentially best-in-class biologics and advances them from discovery to market, using research, development, and strategic collaborations. Its products are engineered biologics—lab-made medicines designed to interact with the body's systems to treat diseases for which there are unmet medical needs. The company differentiates itself through its backing from Paragon Therapeutics and Fairmount, and by leveraging Paragon’s discovery-stage assets to pursue a focused pipeline with potential partnerships and licensing opportunities. Its goal is to bring effective biologic treatments to patients, generate revenue from product sales, licensing deals, and partnerships, and protect patient data while working with compliant support providers.

Company Size

51-200

Company Stage

Post IPO Equity

Headquarters

Waltham, Massachusetts

Founded

2024

Get referred to Jade Biosciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • On June 5, 2026, Jade closed a $150 million offering, extending runway into 2028.
  • Phase 2 JUNIPER began May 26, 2026, accelerating registrational planning for 2027.
  • Mark Eisner joined June 26, 2026, adding Vir, Genentech, and Roche experience.

What critics are saying

  • Vera's atacicept won FDA approval July 2026, crowding Jade's IgAN window.
  • Otsuka's VOYXACT approved November 2025, setting a selective APRIL benchmark before Jade's Phase 3.
  • Jade still depends on JADE101; failure in 2027 likely forces dilution or shutdown.

What makes Jade Biosciences unique

  • JADE101 showed femtomolar APRIL binding and 12-week IgA suppression on June 1, 2026.
  • Paragon Therapeutics and Fairmount built Jade's pipeline, following Apogee, Spyre, and Oruka.
  • JADE201 and JADE301 diversify beyond JADE101, spanning BAFF-R and undisclosed antibodies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

27%

1 year growth

27%

2 year growth

47%
Citybiz
Jun 26th, 2026
Jade Biosciences appoints Dr. Mark Eisner to Board of Directors.

Jade Biosciences appoints Dr. Mark Eisner to Board of Directors. June 26, 2026 Dr. Mark Eisner Jade Biosciences (Nasdaq: JBIO) has appointed biopharmaceutical executive Dr. Mark Eisner to its board of directors, effective June 25, 2026, adding a veteran drug development leader as the clinical-stage biotechnology company advances its pipeline of antibody-based therapies for autoimmune diseases. Eisner brings more than 25 years of experience in clinical development, immunology and regulatory strategy, with a track record spanning early-stage research through global product approvals and commercialization. His appointment comes as Jade continues developing multiple antibody candidates targeting autoimmune disorders, including its lead program for immunoglobulin A (IgA) nephropathy. "We are pleased to welcome Dr. Eisner to the board," said Tom Frohlich, chief executive officer of Jade Biosciences. "Mark's biopharmaceutical executive experience and proven track record guiding innovative therapies from early clinical development through regulatory approval and global commercialization will be highly valuable as Jade rapidly advances its pipeline of antibody-based therapies for autoimmune diseases." Most recently, Eisner served as executive vice president and chief medical officer at Vir Biotechnology, where he led the company's clinical development, regulatory sciences and medical affairs organizations. Before that, he held chief medical officer positions at Sonoma Biotherapeutics and FibroGen. Earlier in his career, Eisner spent nearly 11 years at Genentech/Roche, ultimately serving as senior vice president and global head of product development for immunology, infectious disease and ophthalmology. In that role, he directed multinational clinical development programs and global regulatory submissions across several therapeutic areas, providing experience that aligns with Jade's strategy of advancing novel antibody therapies through clinical development. Prior to joining the biotechnology industry, Eisner was a professor of medicine and anesthesia at the University of California, San Francisco. "I am excited to join the Board of Directors at Jade as the Company rapidly advances its portfolio of potential best-in-class therapies for multiple autoimmune diseases," Eisner said. "Jade is well-positioned to address areas of substantial unmet need for patients, and I look forward to contributing as a board member to support the impact." Jade Biosciences is developing therapies for autoimmune diseases where treatment options remain limited. Its lead clinical candidate, JADE101, targets the cytokine APRIL and is currently being evaluated for the treatment of immunoglobulin A nephropathy, a chronic kidney disease driven by abnormal immune system activity. The company's broader pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an undisclosed antibody program. Jade was launched around assets licensed from Paragon Therapeutics, an antibody discovery company founded by Fairmount. By adding Eisner to its board, Jade strengthens its clinical and regulatory expertise as it advances multiple antibody programs through development, with a focus on translating promising immunology research into therapies for patients with autoimmune diseases.

Jade Biosciences, Inc.
Jun 4th, 2026
Jade Biosciences Announces Pricing of Public Offering of Common Stock - Jade Biosciences

SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) — Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the pricing of a public offering of 10,000,000 shares of its common stock. The shares of common stock are being … Continued

StockTitan
Jun 4th, 2026
Jade Biosciences prices $150M public offering at $15.00 per share

Jade Biosciences has priced a public offering of 10 million common shares at $15.00 per share, expecting gross proceeds of $150 million before expenses. Underwriters have a 30-day option to purchase up to an additional 1.5 million shares. The clinical-stage biotechnology company, focused on autoimmune disease therapies, will use net proceeds alongside existing cash to fund clinical trials, preclinical studies, manufacturing, research and development, capital expenditures and working capital. The offering is expected to close on 5 June 2026. Jefferies, TD Cowen and UBS Investment Bank are acting as joint book-running managers, with LifeSci Capital as passive book-running manager and BTIG as lead manager. The shares are being offered pursuant to an effective Form S-3 shelf registration statement.

StockTitan
Dec 15th, 2025
Jade Biosciences secures $45M private placement from BB Biotech at $14 per share

Jade Biosciences has raised $45 million in a private placement led by BB Biotech, selling 3,214,286 shares of common stock at $14.00 per share. The transaction is expected to close on 16 December 2025, subject to customary closing conditions. The clinical-stage biotechnology company, which focuses on autoimmune disease therapies, will use proceeds to fund research and development, general corporate expenses and working capital. The shares are unregistered, and Jade has agreed to file a registration statement with the SEC to enable resale under a registration rights agreement. This marks Jade's second significant capital raise in recent months, following a $135 million private placement in October 2025. The company is currently developing JADE101, targeting cytokine APRIL for immunoglobulin A nephropathy treatment.

BioWorld
Oct 8th, 2025
Jade Biosciences discloses JADE-201 for autoimmune diseases

Jade Biosciences Inc. has unveiled JADE-201, a monoclonal antibody.